

Biotechnology of Antibiotics

Second Edition, Revised and Expanded

edited by

William R. Strohl
*The Ohio State University
Columbus, Ohio*



MARCEL DEKKER, INC. NEW YORK • BASEL • HONG KONG

ISBN: 0-8247-9867-8

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the address below.

This book is printed on acid-free paper.

Copyright © 1997 by MARCEL DEKKER, INC. All Rights Reserved.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

MARCEL DEKKER, INC.
270 Madison Avenue, New York, New York 10016
<http://www.dekker.com>

Current printing (last digit):
10 9 8 7 6 5 4 3 2 1

PRINTED IN THE UNITED STATES OF AMERICA

14

Lipopeptide Antibiotics Produced by *Streptomyces roseosporus* and *Streptomyces fradiae*

Richard H. Baltz

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

I. INTRODUCTION

Streptomyces roseosporus NRRL11379 produces A21978C, a complex of acidic lipopeptide antibiotics (1). The cyclic depsipeptide portion (Figure 1a) contains 13 amino acids cyclized to form a 10-amino-acid ring. The A21978C factors contain different 10-, 11-, 12-, or 13-carbon fatty acids attached to the amino-group of the terminal L-Trp (1). The fatty acid side chains are readily removed by incubation with *Actinoplanes utahensis* (2), and the cyclic peptide can be reacylated at the amino-terminus of Trp to produce semi-synthetic acyl, aroyl, and extended peptide derivatives (3). The *n*-decanoyl analog of A21978C, LY146032 or daptomycin, is a potent antibiotic active against Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus*, methicillin-resistant *Staphylococcus epidermidis*, vancomycin-resistant enterococci, and penicillin-resistant *Streptococcus pneumoniae* (see Section IV). *Streptomyces fradiae* A54145 also produces a complex of cyclic lipopeptides containing 13 amino acids with a 10-amino-acid ring (4,5). The A54145 complex is similar to daptomycin in that different factors contain various long-chain fatty acids attached to the *N*-terminal Trp (Figure 1b). A54145 differs from daptomycin in that the cyclic peptide is variable in positions 12 and 13, and all four possible peptides are observed in normal fermentations (4,5).

In addition to the *N*-terminal Trp, A54145 contains some amino acids identical or similar to those in daptomycin in other positions, including the position 4 Thr, which participates in the ester linkage that closes the ring. A54145 factors have *in vitro* antibacterial properties similar to those of daptomycin (see Section IV). The fatty acyl side chains of A54145 can be removed by incubation with *A. utahensis* (6), and the *N*-terminal Trp can be reacylated (6), just as with the daptomycin nucleus (2,3).

The similarities in the structures of these two lipopeptides suggest that the biosynthetic pathways may have evolved from a common ancestral pathway. Thus, the study of the structural organization and physical map locations of the biosynthetic genes may provide insights into the evolution of these complex lipopeptide pathways. Further, the diversity in amino acid sequence in these related molecules suggests that further modifi-

cation of the peptide portion of these cyclic peptides may generate as yet unknown, but related antibiotics—some of which may prove to be superior to either of the parent molecules. In this chapter, I summarize what is known about the genetics, biosynthesis, mode of action, and antibacterial activity of these antibiotics. I also speculate on how the activities of these molecules may be further altered by modifying the genes encoding the multienzyme peptide synthetases involved in determining the amino acid sequences of the peptide portion of the molecules.

II. BIOSYNTHESIS OF LIPOPEPTIDES

A. Daptomycin Biosynthesis

S. roseosporus produces A21978C, a complex of lipopeptide antibiotics highly active against Gram-positive bacteria (1). The A21978C complex was separated into three major factors, C₁, C₂, and C₃, and three minor factors, C₄, C₅, and C₀ (Table 1). All six factors contain an identical 13-amino-acid core cyclic peptide, containing 11 common L- or D-amino acids and 2 unusual amino acids, 3-methyl glutamic acid (3mGlu), and the L-tryptophan metabolite L-kynurenine (L-Kyn). Enzymatic studies employing glutamine synthetase and L-glutamic acid decarboxylase established that the stereochemistry of the glutamate analog as L-threo-3-methyl glutamic acid (1). The linear sequence of the peptide core was established as L-Trp-L-Asn-L-Arg-L-Thr-Gly-L-Orn-L-Asp-D-Ala-L-Asp-Gly-D-Ser-L-3mGlu-L-Kyn. The cyclic depsipeptide is formed by an ester linkage between L-Kyn and the L-Thr hydroxyl-group (Figure 1). The factors C₁, C₂, and C₃ were shown to contain *anteiso*-undecanoyl (C11), *iso*-dodecanoyl (C12), and *anteiso*-tridecanoyl (C13) side chains, respectively. The minor components C₀, C₄, and C₅ contain C10, C12, and C12 fatty acids (1). The ratios of factors C₁, C₂, and C₃, which are normally about 1:1.5:1, can be modulated by adding different branched-chain amino acids to the fermentation medium. Factor C₂ can be increased by adding valine to the fermentation, whereas factors C₁ and C₃ can be increased by adding isoleucine (7). The authors concluded that the branched-chain amino acids served as precursors to provide the branched-chain fatty acid primers for the biosynthesis of the fatty acid side chains of the A21978C factors.

Daptomycin, which contains the C10 fatty acid decanoic acid, is normally produced by *S. roseosporus* in trace amounts. Huber et al. (8) have shown that decanoic acid mixed 1:1 (v:v) in methyl oleate can be fed continuously to fermenters at rates that avoid the accumulation of decanoic acid, which is normally toxic to *S. roseosporus*. Under these conditions, *S. roseosporus* A21978.65 produced over 900 µg/ml of daptomycin directly, and less than 400 µg/ml of factors containing other fatty acid side chains. The process was modified for large-scale production, and daptomycin yields of >1000 µg/ml representing 77% of total A21978C factors have been reported (9). High yields of daptomycin can also be produced by feeding caproic acid (10). This process is much simpler and less costly than the process that combines enzymatic removal of the fatty acid side chains and chemical reacylation with decanoic acid (see Section III).

B. A54145 Biosynthesis

The cyclic lipopeptide antibiotic complex A54145 is produced by *S. fradiae* A54145 (NRRL 18158). The complex has eight factors composed of four different cyclic peptides




Figure 1 Structures of daptomycin and A54145B₁. Daptomycin (a) contains an *N*-decanoyl side chain. The A21978C factors produced in standard fermentations contain the fatty acyl side chains shown in Table 1. A54145B₁ (b) is the most abundant factor produced in standard fermentations. The other A54145 factors are shown in Table 2.

Table 1 Lipopeptide A21978C Factors Produced by *S. roseosporus*

Factor	Fatty acid
C ₀	Unidentified (10 carbon)
C ₁	anteiso-Undecanoyl
C ₂	iso-Dodecanoyl
C ₃	anteiso-Tridecanoyl
C ₄	Unidentified (12 carbon)
C ₅	Unidentified (12 carbon)

Data from Ref. 1.

and three different lipid side chains (4,5). The major peptide nucleus has the sequence Trp-Glu-hAsn-Thr-Sar-Ala-Asp-Lys-OmAsp-Gly-Asp-3mGlu-Ile (where hAsn = hydroxy Asn, OmAsp = hydroxymethyl Asp, and 3mGlu = 3-methyl Glu). The peptide is cyclized by an ester linkage between the carboxy-group of Ile and the Thr hydroxy-group. The four different peptide structures are identical in the first 11 amino acids, but have 3mGlu or Glu at position 12 and Ile or Val at position 13. The different peptide structures coupled with three different possible lipid side chains account for the eight factors identified in fermentation broths (Table 2). (Presumably, the four missing factors were present in such low amounts that they were not observed by the high-performance liquid chromatography [HPLC] system used.)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.